Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD

Shots:

  • The Study 102 involves assessing of SRP-9001 vs PBO in 41 patients in a ratio (1:1) with DMD aged 4-7yrs.
  • Results: @12wks. post treatment, the study met its 1EPs of micro-dystrophin protein expression, as measured by western blot. @48wks. increase in NSAA total score, however, the study did not achieve significance on the primary functional endpoint of improvement in NSAA total score @48wks. post-treatment
  • The pre-specified analysis of patients aged 4-5yrs. showed improvement in NSAA total score (4.3 vs 1.9 points). No new safety signals identified for SRP-9001, reinforcing the favorable safety profile

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: The Business Journals

The post Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD first appeared on PharmaShots.